Search This Blog

Monday, February 23, 2026

Protara 68% complete response at six months in Phase 2 for bladder cancer

 

Protara reports 68% complete response at six months with TARA-002 in Phase 2 ADVANCED-2 BCG-unresponsive bladder cancer trial

  • Company plans to complete enrollment of the registrational TARA-002 cohort in ADVANCED-2 in the second half of 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)